Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Prepaid Assets (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Prepaid Assets for 11 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Prepaid Assets fell 3.88% to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 3.88% decrease, with the full-year FY2025 number at $3.0 million, down 3.88% from a year prior.
  • Prepaid Assets was $3.0 million for Q4 2025 at Cartesian Therapeutics, down from $3.2 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $8.2 million in Q2 2021 to a low of $2.0 million in Q2 2024.
  • A 5-year average of $4.5 million and a median of $4.0 million in 2023 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: skyrocketed 686.4% in 2021, then plummeted 52.0% in 2024.
  • Cartesian Therapeutics' Prepaid Assets stood at $6.5 million in 2021, then tumbled by 41.64% to $3.8 million in 2022, then surged by 31.47% to $5.0 million in 2023, then plummeted by 36.7% to $3.1 million in 2024, then fell by 3.88% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Prepaid Assets are $3.0 million (Q4 2025), $3.2 million (Q3 2025), and $2.7 million (Q2 2025).